Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
Business segmentsThe company has 2 business segments: Formulation and API.[1]
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Sun Pharma.Inds. | 1668.90 | 34.69 | 400460.33 | 0.96 | 3124.95 | 2.56 | 14478.31 | 8.93 | 20.21 | 54964.01 | 30.12 | 11543.96 | 3117.95 | 5.15 | 12.97 | 0.07 |
| 2. | Divi's Lab. | 6236.00 | 66.61 | 165513.66 | 0.48 | 689.00 | 35.10 | 2715.00 | 16.12 | 20.44 | 10029.00 | 32.37 | 2485.00 | 689.00 | 10.74 | 13.53 | 0.01 |
| 3. | Torrent Pharma. | 4018.20 | 62.75 | 135955.09 | 0.80 | 591.00 | 32.49 | 3302.00 | 14.30 | 27.05 | 12248.00 | 32.60 | 2166.53 | 600.17 | 16.10 | 13.26 | 0.33 |
| 4. | Cipla | 1397.50 | 20.75 | 112878.16 | 0.93 | 1353.37 | 3.73 | 7589.44 | 7.64 | 22.72 | 28349.57 | 25.40 | 5441.14 | 1351.17 | 3.43 | 14.72 | 0.01 |
| 5. | Lupin | 2177.90 | 23.01 | 99527.00 | 0.55 | 1484.83 | 73.34 | 7047.51 | 24.23 | 21.30 | 24750.69 | 27.25 | 4324.63 | 1477.92 | 5.07 | 12.41 | 0.32 |
| 6. | Dr Reddy's Labs | 1175.50 | 17.00 | 98114.93 | 0.68 | 1336.80 | 7.28 | 8828.30 | 9.83 | 22.69 | 34310.00 | 24.64 | 5772.20 | 1347.10 | 2.72 | 12.95 | 0.16 |
| 7. | Mankind Pharma | 2175.40 | 51.37 | 89821.63 | 0.05 | 520.18 | -22.00 | 3697.16 | 20.77 | 15.98 | 13545.67 | 24.12 | 1748.55 | 511.51 | 5.87 | 8.89 | 0.55 |
| 8. | Sequent Scien. | 193.73 | 539.37 | 8419.50 | 0.00 | 3.08 | -45.30 | 34.03 | -18.96 | 2.40 | 153.70 | -7.79 | 15.61 | 3.90 | 4.13 | 1.42 | 0.02 |
| – | Median: 149 Co. | 392.6 | 30.0 | 1767.16 | 0.12 | 13.49 | 9.76 | 161.22 | 10.54 | 14.89 | 591.73 | 15.93 | 45.26 | 13.96 | 3.13 | 8.56 | 0.21 |
Standalone figures in ₹ crores
| Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 64.86 | 54.23 | 57.00 | 46.60 | 40.42 | 49.12 | 42.21 | 36.77 | 57.67 | 41.99 | 36.27 | 42.33 | 41.07 | 34.03 |
Expenses | 66.85 | 63.81 | 65.74 | 52.64 | 49.49 | 56.82 | 46.36 | 42.53 | 59.65 | 44.09 | 40.75 | 45.15 | 43.11 | 36.67 |
Operating Profit | -1.99 | -9.58 | -8.74 | -6.04 | -9.07 | -7.70 | -4.15 | -5.76 | -1.98 | -2.10 | -4.48 | -2.82 | -2.04 | -2.64 |
Other Income | 5.88 | 6.73 | 7.62 | 8.01 | 3.45 | 9.87 | 13.44 | 12.98 | 10.84 | 11.63 | 11.57 | 12.02 | 10.23 | 10.05 |
Profit before tax | 1.16 | -5.68 | -3.99 | -1.23 | -9.03 | -1.39 | 6.09 | 4.10 | 6.05 | 6.41 | 3.68 | 5.91 | 4.78 | 4.34 |
Tax % | 27.59% | -28.70% | -69.42% | 34.15% | -24.70% | -34.53% | 24.79% | 8.29% | 25.62% | 33.54% | 23.64% | 28.43% | 29.50% | 29.03% |
Net Profit | 0.84 | -4.05 | -1.23 | -1.65 | -6.80 | -0.92 | 4.58 | 3.76 | 4.50 | 4.26 | 2.81 | 4.23 | 3.37 | 3.08 |
EPS in Rs | 0.03 | -0.16 | -0.05 | -0.07 | -0.27 | -0.04 | 0.18 | 0.15 | 0.18 | 0.17 | 0.11 | 0.17 | 0.13 | 0.12 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 341 | 384 | 395 | 91 | 106 | 166 | 227 | 265 | 220 | 223 | 169 | 178 | 154 |
Expenses | 347 | 330 | 358 | 121 | 124 | 164 | 205 | 230 | 220 | 249 | 195 | 190 | 166 |
Operating Profit | -6 | 54 | 36 | -31 | -18 | 3 | 22 | 35 | -1 | -26 | -27 | -11 | -12 |
Other Income | -55 | 57 | 15 | 34 | 432 | 14 | 15 | 17 | 28 | 28 | 40 | 46 | 44 |
Interest | 31 | 43 | 16 | 0 | 0 | 3 | 5 | 3 | 2 | 3 | 4 | 4 | 4 |
Depreciation | 23 | 25 | 24 | 3 | 4 | 7 | 9 | 9 | 10 | 9 | 9 | 9 | 9 |
Profit before tax | -114 | 43 | 10 | -0 | 409 | 6 | 23 | 41 | 16 | -10 | -0 | 22 | 19 |
Net Profit | -114 | 41 | 10 | -0 | 406 | 8 | 21 | 32 | 15 | -6 | 1 | 16 | 13 |
EPS in Rs | -8.38 | 2.71 | 0.44 | -0.00 | 16.68 | 0.31 | 0.86 | 1.29 | 0.60 | -0.24 | 0.02 | 0.63 | 0.53 |
Dividend Payout % | 0% | 0% | 0% | 0% | 1% | 65% | 0% | 39% | 0% | 0% | 0% | 0% | – |
Standalone figures in ₹ crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 27 | 30 | 48 | 49 | 49 | 49 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
Reserves | 24 | 126 | 1,158 | 1,209 | 900 | 868 | 837 | 980 | 991 | 1,008 | 1,037 | 1,093 | 1,131 |
Borrowings | 350 | 341 | 49 | 87 | 0 | 44 | 35 | 6 | 17 | 20 | 47 | 46 | 23 |
Other Liabilities | 160 | 153 | 94 | 106 | 29 | 57 | 76 | 67 | 66 | 44 | 54 | 34 | 29 |
Total Liabilities | 560 | 650 | 1,348 | 1,450 | 977 | 1,019 | 997 | 1,102 | 1,124 | 1,123 | 1,188 | 1,222 | 1,233 |
Fixed Assets | 220 | 201 | 170 | 188 | 24 | 52 | 69 | 66 | 67 | 57 | 43 | 46 | 47 |
Gross Block | 338.33 | 302.01 | 193.00 | 236.73 | 37.61 | 73.33 | 99.30 | 102.86 | 113.09 | 105.70 | 87.15 | 94.39 | – |
Accumulated Depreciation | 118.40 | 101.13 | 23.40 | 48.88 | 13.93 | 20.90 | 29.89 | 37.08 | 46.19 | 48.98 | 44.62 | 48.21 | – |
CWIP | 11 | 9 | 20 | 32 | 3 | 0 | 4 | 4 | 1 | 2 | 5 | 7 | 1 |
Investments | 65 | 183 | 897 | 891 | 687 | 788 | 758 | 685 | 659 | 633 | 640 | 647 | 653 |
Other Assets | 264 | 257 | 262 | 340 | 264 | 178 | 167 | 347 | 397 | 431 | 500 | 522 | 532 |
Total Assets | 560 | 650 | 1,348 | 1,450 | 977 | 1,019 | 997 | 1,102 | 1,124 | 1,123 | 1,188 | 1,222 | 1,233 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | -42 | -25 | 100 | -24 | -4 | 74 | 30 | 2 | 9 | 38 | -27 | -1 |
Cash from Investing Activity | -61 | 24 | -359 | -47 | 16 | -114 | -18 | 17 | -4 | -51 | 5 | -0 |
Cash from Financing Activity | 108 | 8 | 247 | 71 | -12 | 40 | -11 | -21 | 7 | 0 | 22 | 1 |
Net Cash Flow | 4 | 7 | -12 | 0 | -0 | 0 | 2 | -2 | 12 | -13 | 1 | -1 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 85 | 94 | 68 | 455 | 270 | 94 | 65 | 84 | 87 | 22 | 97 | 141 |
Inventory Days | 196 | 126 | 94 | 315 | 64 | 98 | 101 | 154 | 228 | 129 | 117 | 87 |
Days Payable | 262 | 132 | 123 | 352 | 113 | 203 | 208 | 197 | 193 | 99 | 126 | 79 |
Cash Conversion Cycle | 19 | 88 | 39 | 417 | 221 | -11 | -41 | 41 | 122 | 53 | 88 | 148 |
Working Capital Days | -207 | -202 | 115 | 541 | 333 | 12 | -6 | 65 | 87 | 22 | -5 | 64 |
ROCE % | -6% | 24% | 3% | 0% | 35% | 1% | 3% | 5% | 2% | -1% | 1% | 2% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Nov 2025
Nov 2025
Nov 2025
Aug 2025
Aug 2025
May 2025
Feb 2025
Nov 2024
Oct 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Feb 2023
Nov 2022
Aug 2022
May 2022
Nov 2021
Aug 2021
Feb 2021
Dec 2020
Nov 2020
Jul 2020
May 2020
Jan 2020
Nov 2019
Jul 2019
May 2019
Jan 2019
Nov 2018
Aug 2018
Stock Analysis
Viyash Scientific Limited, formerly known as Sequent Scientific Limited, is a prominent animal health pharmaceutical company with a significant global footprint. Symed Labs, which has now been amalgamated into the Viyash Scientific structure, is a manufacturer of active pharmaceutical ingredients (APIs) with USFDA-approved facilities.
Currently no data available for Key Growth Triggers.
Currently no data available for Order Book.
CRISIL's withdrawal of ratings for Symed Labs Ltd is a procedural consequence of its amalgamation and subsequent cessation of existence as an independent entity. This indicates a structural change rather than a performance-related red flag.
Corporate Announcements
